Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909464 | 0.79 | L3MBTL1 (0.34) | LTA4HTSHRALDH1A1L3MBTL1KMT2A | |
| SCHEMBL6902736 | 0.79 | LTA4H (0.34) | LTA4HTSHRALDH1A1L3MBTL1KMT2A | |
| SCHEMBL6908568 | 0.78 | L3MBTL1 (0.42) | LTA4HTSHRALDH1A1L3MBTL1KMT2A | |
| SCHEMBL6903481 | 0.75 | ALDH1A1 (0.42) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6905964 | 0.75 | PKM (0.37) | LTA4HALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL6908589 | 0.74 | LTA4H (0.39) | LTA4HTSHRALDH1A1L3MBTL1KMT2A | |
| SCHEMBL6909195 | 0.73 | ALDH1A1 (0.45) | LTA4HTSHRALDH1A1L3MBTL1KMT2A | |
| SCHEMBL6909741 | 0.72 | LMNA (0.43) | LTA4HL3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL6903538 | 0.72 | MAPT (0.41) | LTA4HTSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL6909270 | 0.71 | LTA4H (0.37) | LTA4HTSHRALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | ATHEROGENICS, INC. (US) | 2003-09-18 | — | — | US | claimed |
| US-6747061-B2 | ADMINISTERING AN ANTIPROLIFERATIVE AGENT IN COMBINATION WITH A POTENTIATING EFFECTIVE AMOUNT OF A N- SUBSTITUTED DITHIOCARBAMATE ESTER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ATHEROGENICS, INC. | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | VCAM1, MKI67, SELL | LTA4H 1855/4885TSHR 3397/4885ALDH1A1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.